Cristiane Bedran Milito

Cristiane Bedran Milito

Auto-generated profile, based on publicly available information

Cristiane Bedran Milito

Department of Pathology School of Medicine Clementino Fraga Filho University Hospital Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
BABruno Augusto Benevenuto de Andrade
Bruno Augusto Benevenuto de Andrade
MFMaria Danielle Fontes
Maria Danielle Fontes
ARAna Luiza Oliveira Corrêa Roza
Ana Luiza Oliveira Corrêa Roza
Pablo VargasPablo Vargas
Pablo Vargas
MAMichelle Agostini
Michelle Agostini
MRMário José Romañach
Mário José Romañach

5 June 2021 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
JAJosé Alcides Almeida de Arruda
José Alcides Almeida de Arruda
TAThamiris de Castro Abrantes
Thamiris de Castro Abrantes
JCJohn Lennon Silva Cunha
John Lennon Silva Cunha
ARAna Luiza Oliveira Corrêa Roza
Ana Luiza Oliveira Corrêa Roza
MAMichelle Agostini
Michelle Agostini
BABruno Augusto Benevenuto de Andrade
Bruno Augusto Benevenuto de Andrade

1 February 2020 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
JGJoão dos Santos Gonçalves
João dos Santos Gonçalves
FCFabiano Lacerda Carvalho
Fabiano Lacerda Carvalho
ICIgor Cabral Do Rego Coutinho
Igor Cabral Do Rego Coutinho
JMJosé Carlos Oliveira Morais
José Carlos Oliveira Morais
RFRodrigo Soares Fortunato
Rodrigo Soares Fortunato
CMCristiane Bedran Milito
Cristiane Bedran Milito
SUMMARY OBJECTIVES Lymphomas are a heterogeneous set of malignant neoplasias of lymphoid B and NK/T mature and immature cells at various stages of differentiation. Genetic and molecular biology tools are used to appropriately classify the type and prognosis of the lymphomas, which have implications in therapeutic effectiveness. Among them, the nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) oxidase (NOX5) enzymes have been explored. This study analyzed the expression of NADPH oxidase 5 in lymphoma tissue according to the degree of tumor aggressiveness. METHODS Slides from 64 patients with lymphoma who had paraffin-embedded tissue available were reviewed by two independent, experienced pathologists. They classified tumors according to the WHO classification (2017). NOX5 expression in tissues was assessed by immunohistochemical staining using a tissue microarray. The assay was interpreted using a scoring system of 0, 1, 2, and 3, for cytoplasmic staining of NOX5 corresponding to negative, weak, intermediate, and strong staining, respectively. We compared the expression of NOX5 in patients with aggressive versus non-aggressive lymphomas. RESULTS NOX5 expression was positive in 100% (27/27) of aggressive lymphomas and in 19% (7/37) of non-aggressive ones. The seven patients with positive expression of NOX5 presented intermediate staining (2); strong staining (3) was observed only in tissues of aggressive lymphomas, and negative and weak staining (0 and 1) were observed only in non-aggressive lymphomas. CONCLUSIONS Aggressive lymphomas overexpress NOX5 protein. The higher NOX5 expression in aggressive lymphomas can suggest an involvement of this enzyme on the acquisition of an aggressive phenotype in lymphoid neoplasia.

17 August 2026 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
DQDanielle Carvalho Quintella
Danielle Carvalho Quintella
CMCristiane Bedran Milito
Cristiane Bedran Milito
TCTullia Cuzzi
Tullia Cuzzi

25 November 2019 in Human Pathology: Case Reports
Verified
Journal Article
Open access
PDF file
CMCristiane B. Milito
Cristiane B. Milito
FBFrancisco Beca
Francisco Beca
YNYasodha Natkunam
Yasodha Natkunam
SCStephen Cook
Stephen Cook
We report a case of breast implant-associated anaplastic large cell lymphoma in a 70-year old woman, who 21 years previously had undergone bilateral breast augmentation with textured silicone implants. Eleven years later, she had bilateral implant removal with possible implant leak and presence of ‘atypical cells’ in the seroma. She then opted for prophylactic bilateral mastectomy in view of her strong family history of breast cancer and underwent reconstruction with subcutaneous gel implants. Eight months later, the patient noted right breast swelling and peri-implant effusion. The cytology was suspicious for lymphoma. Bilateral implant removal and capsulectomy was performed and a breast implant-associated anaplastic large cell lymphoma was diagnosed. Due to the lack of surrounding breast tissue after mastectomy, it was not possible to thoroughly sample or evaluate breast parenchymal involvement by the lymphoma, an important consideration in determining aggressivity. The decision was made to initiate Brentuximab vedotin therapy.

1 January 2026 in Arquivos Brasileiros de Oftalmologia
Verified
Journal Article
Closed access
RPRenata Sande Paiva
Renata Sande Paiva
CMCristiane Bedran Milito
Cristiane Bedran Milito
DCDiogo Goulart Corrêa
Diogo Goulart Corrêa
NVNina Ventura
Nina Ventura
SJSérgio Ferreira Alves Júnior
Sérgio Ferreira Alves Júnior